Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year. Coverage brought to you by

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide. Coverage brought to you by

CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal. Coverage brought to you by

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by

He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy. Coverage brought to you by

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data. Coverage brought to you by

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program. Coverage brought to you by

Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by

He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific. Coverage brought to you by

He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.

Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction. Biographies Reenie McCarthy is the Chief Executive Officer, President and a member of t

CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS. Coverage brought to you by

He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans. Coverage brought to you by

He comments on Kymera, Apogee, Avalo, Veridian, Moonlake, Spyre, and Oruka. Coverage brought to you by

He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond. Coverage brought to you by

He comments on IPOs, fundraising, M&A, and China. Coverage brought to you by